Evommune (EVMN) Operating Expenses (2024 - 2026)

Evommune (EVMN) has reported Operating Expenses for 3 consecutive years, with $24.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 32.84% year-over-year to $24.0 million; the TTM figure through Mar 2026 stood at $95.0 million (changed N/A YoY), while the FY2025 annual figure was $94.1 million, up 22.15% from the prior year.
• Operating Expenses eased to $24.0 million in Q1 2026 per EVMN's latest filing, from $29.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $29.7 million in Q4 2025 and bottomed at $16.5 million in Q3 2024.
• Historically, Operating Expenses has averaged $22.2 million across 3 years, with a median of $22.4 million in 2024.
• Annual changes were most pronounced in 2025 — Operating Expenses soared 41.24% — and 2026, when it jumped 32.84%.
• Evommune's Operating Expenses stood at $21.5 million in 2024, then surged by 38.51% to $29.7 million in 2025, then retreated by 19.39% to $24.0 million in 2026.
• Business Quant data shows EVMN's Operating Expenses at $24.0 million in Q1 2026, $29.7 million in Q4 2025, and $23.3 million in Q3 2025.